RSV in Adults who have Coronary Artery Disease (CAD), Congested Heart Failure (CHF) or those that have had Solid Organ Transplants
This is a Phase 3 study to evaluate the safety and effectiveness of an mRNA vaccine targeting Respiratory Syncytial Virus (RSV) in:
- People who have Coronary Artery Disease (CAD). OR - People who have Congested Heart Failure (CHF) OR - Those that have had a Solid Organ Transplant (Lung, Kidney, and Liver).
RSV (Respiratory Syncytial Virus) is a common cause of severe respiratory disease in immunocompromised adults, and in solid organ transplant recipients. RSV is associated with significant morbidity and mortality.
You can contact our office at 501-500-4270 or fill out the short "Do You Qualify" Questionnaire to see if you qualify for this study.
Compensation* Up to $3,000 for study related time and travel
Study Topics Evaluating a vaccine for RSV in Adults who have Coronary Artery Disease (CAD), Congested Heart Failure (CHF), or those that have had Solid Organ transplants
*Compensation for time and travel may be available to those who qualify.
Don’t meet the criteria of this trial but want to participate?
Contact us to be added to our database and you’ll be first to know about our future studies that may be right for you.